Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseMarc S. Sabatine, Terje R. Pedersen, Stephen D. Wiviott et al.|New England Journal of Medicine|2017Cited by 6k
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trialMarc S. Sabatine, Terje R. Pedersen, Lawrence A. Leiter et al.|The Lancet Diabetes & Endocrinology|2017Cited by 595
F-box Protein FBXL16 Binds PP2A-B55α and Regulates Differentiation of Embryonic Stem Cells along the FLK1+ LineageNarimon Honarpour, Raymond J. Deshaies|Molecular & Cellular Proteomics|2014Cited by 28